Results 221 to 230 of about 77,108 (288)

Real-World Outcomes of Ipilimumab-Nivolumab vs. Anti-PD-1 Monotherapy in Metastatic Uveal Melanoma: A Single-Center Retrospective Study. [PDF]

Cancers (Basel)
Pánczél G, Horváth P, Temaj E, Czirbesz K, Kispál MT, Fröhlich G, Balatoni T.   +6 more
europepmc   +1 more source

Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials. [PDF]

BMJ Open
Peinemann F, Baradaran S, Arnolds KB, Hoemberg M.   +3 more
europepmc   +1 more source

Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. [PDF]

Front Immunol
Park J, Skålhegg BS.
europepmc   +1 more source

Early severe immune-related pneumonitis, hepatitis, and agranulocytosis with radiographic response in sarcomatoid malignant pleural mesothelioma treated with nivolumab and ipilimumab: a case report highlighting dual liver biopsies and rechallenge decision-making. [PDF]

Ther Adv Med Oncol
Oba T, Itogawa K, Machida Y, Ono Y, Morita Y, Nakatani D, Akasaka K, Adachi A, Matsushima H.   +8 more
europepmc   +1 more source

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma. [PDF]

Front Immunol
Ajani JA, Smyth E, Tougeron D, Jung HA, Tang W, Steenkamp J, Prentiss E, Coaquira Castro J, Szafranski K, Zhan L.   +9 more
europepmc   +1 more source

Design and Characterization of Prodrugged Anti-CTLA-4 Antibodies. [PDF]

Chembiochem
Yamazoe S, Huber M, Kotapati S, Akter R, Jashnani A, Deol S, Bee C, Engelhart J, Poudel YB, Krystek S, Haugner J, Srinivasan M, Rajpal A, Zhang Y, Strop P, Rao C.   +15 more
europepmc   +1 more source

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU). [PDF]

BMC Cancer
Sakanaka K, Sasaki K, Tsushima T, Machida R, Hamai Y, Watanabe A, Kawabata K, Matsuda S, Kato K, Fukuda H, Takeuchi H, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group.   +11 more
europepmc   +1 more source

Systematic review on the safety and efficacy of immune checkpoint inhibitors combined with stereotactic body radiotherapy in advanced pancreatic cancer. [PDF]

Clin Exp Med
Magashi MA, Danbala IA, Shaibu Z, Abdullahi MM, Cai H.   +4 more
europepmc   +1 more source

Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases. [PDF]

J Neurooncol
Boffelli L, Fimiani C, Núñez NG, Kienzler JC.   +3 more
europepmc   +1 more source

Immunotherapy for pleural mesothelioma: from innovation to the frontlines of core clinical questions. [PDF]

Discov Oncol
Yoshida T, Kuribayashi K.
europepmc   +1 more source